Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q3 FY2010 Earnings Presentation

15 slides from Daiichi Sankyo's earnings presentation, Jan 31, 2011

  1. Slide 1: Results for Q3 FY2010

    Results for Q3 FY2010 (April 1 – December 31, 2010) January 31, 2011 Manabu Sakai, Executive Officer

  2. Slide 2: Results Overview

    Results Overview

  3. Slide 3: Overview of FY2010 Q3 YTD Results

    Overview of FY2010 Q3 YTD Results (Billions of yen) Net Sales Operating Income 800.0 125.0 120.6 748.1 600.0 725.7 100.0 75.0 90.1 400.0 50.0 200.0 25.0 0.0 0.0 FY2009 Q3YTD FY2010 Q3YTD FY2009 Q3YTD FY2010 Q3YTD Ordinary Income Net Income 125.0 100.0 130.6 100.0 80.0 79.7 75.0 90.6 60.0 50.0 40.0 3

  4. Slide 4: Overview of FY2010 Q3 YTD Results - compared with FY2009 Q3 YTD

    Overview of FY2010 Q3 YTD Results - compared with FY2009 Q3 YTD - (Billions of yen, ratio to sales) FY2009 FY2010 Ranbaxy Q3 YTD Q3 YTD YoY 2009 Jan-Sep 2010 Jan-Sep YoY Results Results (2)-(1) Results Results (4)-(3) (1) (2) (3) (4) 100.0% 100.0% 100.0% 100.0% Net Sales 725.7 748.1 22.4 102.2 134.2

  5. Slide 5: Year-on-Year Comparisons

    Year-on-Year Comparisons 1. Net Sales ¥748.1 billion (+¥22.4 billion, +3.1%) „ Positive factors ・ Ranbaxy contribution centering on Valacyclovir (+¥31.8 billion) ・ Olmesartan (+¥6.8 billion) ・ Loxonin (+¥4.5 billion) ・ Milestone payment received on the approval of Denosumab in Europe „ Negative fact

  6. Slide 6: Year-on-Year Comparisons

    Year-on-Year Comparisons 3. Ordinary Income ¥130.6 billion (+¥40.0 billion, +44.1%) „ Factors: ¥9.4 billion improvement in Ranbaxy-related non-operating items ・ Non-operating income (-¥1.5 billion) ・ Non-operating expenses (-¥10.9 billion) Ranbaxy-related (-¥9.9 billion) forex losses, etc. 4. Net In

  7. Slide 7: FY2010 Revised Forecast

    FY2010 Revised Forecast (Billions of yen, ratio to sales) FY2010 FY2010 Forecast Forecast Change Remarks (Oct-2010) (Jan-2011) Performance of certain overseas 100.0% 100.0% Net Sales subsidiaries and OTC business below 980.0 965.0 -15.0 expectation 29.8% 29.0% Cost of Sales 292.0 280.0 -12.0 SG&A 38

  8. Slide 8: Status of Major Business Units

    Status of Major Business Units (Billions of yen) FY2010 Sales Q3 YTD Full Year Progress Results Forecast Daiichi Sankyo Co., Ltd. 325.1 415.0 78.3% Total Net Sales of Ethical Pharmaceuticals Daiichi Sankyo Healthcare Co., Ltd. (DSHC) 34.2 48.5 70.5% Daiichi Sankyo, Inc. (DSI) 102.1 145.0 70.4% Luitp

  9. Slide 9: Sales of Major Products

    Sales of Major Products (Billions of yen) FY2010 Sales Q3 YTD Full Year Results Progress *1 YoY Forecast YoY Olmesartan antihypertensive 186.8 75.0% 6.8 260.0 21.7 GLOBAL Levofloxacin synthetic antibacterial agent 51.9 75.7% -13.5 70.0 -17.2 Pravastatin antihyperlipidemic agent 35.3 81.0% -9.3 44.0

  10. Slide 10: R&D Pipeline Update

    R&D Pipeline Update

  11. Slide 11: Movement since October 2010 update

    Movement since October 2010 update Stage progress ● Application→ Approval SUN Y7017: Memantine, alzheimer's type dementia (JPN) • Brand name: Memary® tablets CS-8635: Triple combo antihypertensive (Olmesartan, Amlodipine, and Hydrochlorothiazide) (EU) • Brand name: Sevikar HCT® ● Phase II → Phase II

  12. Slide 12: Development Pipeline (January 2011)

    Development Pipeline (January 2011) Phase Phase 11 Phase Phase 22 Phase Phase 33 Application Application --Prasugrel Prasugrel(ACS-MM) (ACS-MM) Cardiovascular Cardiovasculardiseases diseases --CS-3150 CS-3150 --Prasugrel Prasugrel(#(# ACS-PCI) ACS-PCI) --Edoxaban Edoxaban(JPN) (JPN) --Edoxaban Edoxa

  13. Slide 13: Daiichi Sankyo Briefings

    Daiichi Sankyo Briefings Date (JST) Ranbaxy Feb 22, 2011 Announcement 2010 Financial Results May 12, 2011 Announcement 2010 Financial Results May 13, 2011 Media/Investors Conference １３

  14. Slide 14: Memo

    © Daiichi-Sankyo

  15. Slide 15: Corporate Communications Department

    Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: +81-3-6225-1126 Public Relations +81-3-6225-1125 Investor Relations Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the

Daiichi Sankyo Company — Q3 FY2010 Earnings Presentation on 6ix